期刊
CANCERS
卷 12, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/cancers12061609
关键词
non-small cell lung cancer; immunotherapies; nanomedicine; cancer vaccine; chemotherapy
类别
资金
- Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) from Generalitat de Catalunya [SGR 2017 1559]
- Spanish Ministerio de Ciencia, Innovacion y Universidades [RTI2018-094734-B-C22]
- IQS
- Fundacio Cellex research grant
Non-small cell lung cancer (NSCLC) remains the most common cause of cancer-related mortality. The heterogeneous nature of this disease hinders its diagnosis and treatment, requiring continuous advances in research aiming to understand its intricate nature. Consequently, the retrospective analysis of conventional therapies has allowed the introduction of novel tools provided by nanotechnology, leading to considerable improvements in clinical outcomes. Furthermore, the development of novel immunotherapies based on the recently understood interaction of the immune system with the tumor highlights the real possibility of definitively treating NSCLC from its early stages. Novel engineering approaches in nanomedicine will enable to overcome the intrinsic limits of conventional and emerging therapies regarding off-site cytotoxicity, specificity, resistance mechanisms, and administration issues. The convergence point of these therapies with nanotechnology lays the foundation for achieving currently unmet needs.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据